2024 Endocrinology Grand Rounds | Beyond the Scale: Insights into Obesity and the Evolution of Drug Therapies
Obesity affects 41.9% US adult population according to NHANES data 2021. Obesity-related conditions include heart disease, stroke, type 2 diabetes and certain types of cancer. These are among the leading causes of preventable, premature death. The estimated annual medical cost of obesity in the United States was nearly $173 billion in 2019 dollars. Medical costs for adults who had obesity were $1,861 higher than medical costs for people with healthy weight. It is imperative to provide an update on the medical management of adiposity-based chronic diseases, in an effort to improve knowledge on current standards of care.
This field has seen remarkable clinical and scientific progress over the last two decades, and as a result, several medical options for management are available, and each requires careful assessment of pros and cons. This up-to-date review of evaluation and management of obesity and related medical conditions will help improve clinicians practice and lead to improved patient care, bringing latest standards into practice, thereby, improving quality of care and patient health.
Target Audience
Faculty and Staff of Department of Diabetes, Endocrinology and Metabolism.
Learning Objectives
- Analyze the epidemiological trends of obesity, associated comorbid conditions and the impact of cultural and socioeconomic differences on public health.
- Evaluate the effectiveness and safety of established and newly approved pharmacological treatments for obesity.
- Discuss upcoming advancements in obesity management, including phase I-III trials of nutrient-stimulated hormone-
- based therapies.
- Develop comprehensive strategies for obesity management that incorporate culturally sensitive lifestyle modifications alongside pharmacological treatment.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
Dimpi Nitin Desai, MD Clinical Assistant Professor, Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University
Presenter: Dr. Desai has indicated that there are no relevant financial relationships.
Dr. Desai will be discussing the off-label or investigational use Phentermine, Topiramate, Metformin, and Bupropion.
Planner: Pooja Manroa, MD has indicated that there are no relevant financial relationships.
This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.
CME Committee/Reviewer no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2024 Endocrinology Grand Rounds | Beyond the Scale: Insights into Obesity and the Evolution of Drug Therapies for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance